Accept Refuse

EUR-Lex Access to European Union law

This document is an excerpt from the EUR-Lex website

Document 62017CN0527

Case C-527/17: Request for a preliminary ruling from the Bundespatentgericht (Germany) lodged on 5 September 2017 — LN

OJ C 402, 27.11.2017, p. 11–12 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

27.11.2017   

EN

Official Journal of the European Union

C 402/11


Request for a preliminary ruling from the Bundespatentgericht (Germany) lodged on 5 September 2017 — LN

(Case C-527/17)

(2017/C 402/13)

Language of the case: German

Referring court

Bundespatentgericht

Parties to the main proceedings

Applicant: LN

Defendant: Deutsches Patent- und Markenamt

Question referred

Must Article 2 of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (1) be interpreted as meaning that, for the purposes of that regulation, an authorisation under Directive 93/42/EEC (2) for a combined medical device and medicinal product within the meaning of Article 1(4) of Directive 93/42/EEC is to be treated as a valid marketing authorisation under Directive 2001/83/EC (3), where, as part of the authorisation procedure laid down in Annex I, Section 7.4, first paragraph, to Directive 93/42/EEC, the quality, safety and usefulness of the medicinal product component has been verified by the medicinal products authority of a Member State in accordance with Directive 2001/83/EC?


(1)  OJ L 152, p. 1.

(2)  Council Directive 93/42/EEC of 14 June 1993 concerning medical devices (OJ 1993 L 169, p. 1).

(3)  Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67).


Top